# CJC-1295 References: The Cited Studies and Reviews

> CJC-1295 references: the peer-reviewed studies and reviews cited across this site, with DOIs and PubMed links — Teichman 2006, Jette 2005, Ionescu/Frohman 2006, Alba 2006, and the GHRH-analog literature.

Every quantitative claim on this site resolves to one of these entries. DOIs and PubMed identifiers included for verification.

## How to read these CJC-1295 references

The inline markers throughout this site — [1], [2], and so on — map to the numbered entries below. Where a study reports a dose, percentage, duration, half-life or sample size, that number is attributable to one of these sources. Primary human pharmacokinetic data come from Teichman 2006 and Ionescu/Frohman 2006; the albumin-bioconjugate design is from Jette 2005; the GHRH-analog class context is from the 2025 Nature Reviews Endocrinology review. Identifiers below are provided so any claim can be checked against the original.

## References

[1] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[2] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009. https://pubmed.ncbi.nlm.nih.gov/19240251/
[8] Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. https://pubmed.ncbi.nlm.nih.gov/12446584/
[9] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing materials reviewing growth hormone secretagogues (including CJC-1295); CJC-1295 not recommended for the 503A bulk drug substances list. 2024. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
[10] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[11] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[12] Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide. Pharm Res. 1999. https://pubmed.ncbi.nlm.nih.gov/10496658/
[13] The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001. https://pubmed.ncbi.nlm.nih.gov/11735244/
[14] Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. https://pubmed.ncbi.nlm.nih.gov/20943777/

---

An after-hours editorial reading of the published CJC-1295 record — the multi-day pharmacokinetics set in hot-pink against the human data that is still missing, with no clinic behind the type and nothing here dispensed or sold.